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Abstract
Background: The transcription factor B-Myb is present in all proliferating cells, and in mice engineered to remove this gene,
embryos die in utero just after implantation due to inner cell mass defects. This lethal phenotype has generally been
attributed to a proliferation defect in the cell cycle phase of G1.
Methodology/Principal Findings: In the present study, we show that the major cell cycle defect in murine embryonic stem
(mES) cells occurs in G2/M. Specifically, knockdown of B-Myb by short-hairpin RNAs results in delayed transit through G2/M,
severe mitotic spindle and centrosome defects, and in polyploidy. Moreover, many euploid mES cells that are transiently
deficient in B-Myb become aneuploid and can no longer be considered viable. Knockdown of B-Myb in mES cells also
decreases Oct4 RNA and protein abundance, while over-expression of B-MYB modestly up-regulates pou5f1 gene
expression. The coordinated changes in B-Myb and Oct4 expression are due, at least partly, to the ability of B-Myb to directly
modulate pou5f1 gene promoter activity in vitro. Ultimately, the loss of B-Myb and associated loss of Oct4 lead to an
increase in early markers of differentiation prior to the activation of caspase-mediated programmed cell death.
Conclusions/Significance: Appropriate B-Myb expression is critical to the maintenance of chromosomally stable and
pluripotent ES cells, but its absence promotes chromosomal instability that results in either aneuploidy or differentiation-
associated cell death.
Citation: Tarasov KV, Tarasova YS, Tam WL, Riordon DR, Elliott ST, et al. (2008) B-MYB Is Essential for Normal Cell Cycle Progression and Chromosomal Stability of
Embryonic Stem Cells. PLoS ONE 3(6): e2478. doi:10.1371/journal.pone.0002478
Editor: Thomas Zwaka, Baylor College of Medicine, United States of America
Received November 29, 2007; Accepted May 19, 2008; Published June 25, 2008
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This research was supported by the Intramural Research Program of the NIA/NIH (KRB, RPW), the German Research Foundation (Wo 503/3-3: AMW), and
NIH grants (R01 HL72857: RAL).
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: bohelerk@grc.nia.nih.gov
Introduction
Avian myeloblastosis viral oncogene homolog-2 (mybl2)i sa
member of a multigene family of transcription factors involved in
control of cell cycle progression, differentiation and apoptosis
[1,2]. All members of this family, A-MYB, B-MYB (MYBL2) and
C-MYB, contain conserved regulatory and transactivation do-
mains that exhibit sequence-specific DNA-binding activity [3]; and
in vitro, each protein can bind to the same consensus sequence C/
TAACNG [1]. B-MYB is, however, a relatively poor transacti-
vator when compared with either A- or C-Myb. Among tissues, C-
MYB is most prevalent in bone marrow and is critical to
generation of definitive hematopoietic stem cells [4]; whereas, A-
MYB is abundant in testes and is implicated in normal
spermatogenesis and in mammary gland proliferation [5]. Only
B-MYB, the ancestral gene of this family, is expressed in all
proliferating cells [6].
As with many cell cycle associated transcription factors, B-Myb
expression and function is dynamically regulated. The mybl2 gene,
which encodes B-Myb, is regulated directly by E2F transcription
factors and is maximally induced at the G1/S boundary of the cell
cycle [2,7]. The trans-activation and gene regulatory potential of B-
MYB is regulated by cyclin A/cdk2-mediated phosphorylation [8],
and B-MYB is degraded through a ubiquitin-mediated process late
in S phase [9]. Because it is prevalent during both late G1 and
early S phases, the primary functions of B-MYB have generally
been assumed to be restricted to these portions of the cell cycle
[2,7,10]; however, studies in Drosophila [11,12] and zebrafish [13]
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condensation, chromosomal stability and cell cycle progression
through G2/M.
Importantly, B-Myb is the only member of this multigene family
known to be present in embryonic stem (ES) cells, and
developmentally, knockout of this gene results in embryonic
lethality by 6.5 dpc in mice. Essentially this transcription factor is
thought to be necessary for continued growth of the inner cell mass
during the post-implantation phase of development [14]. Although
the mechanism responsible for this lethality has generally been
attributed to a defect in cell cycle progression through G1, based
on studies using a dominant-negative and inducible form of C-
Myb [15], neither the molecular basis of embryonic lethality nor
its function in ES cells has been evaluated. In the present study, we
show that B-MYB is required not only for normal ES cell cycle
progression but also for correct mitotic spindle formation and
maintenance of euploidy. Moreover, knockdown of B-Myb in ES
cells promotes either differentiation coupled to apoptosis or
generation of aneuploid ES cells.
Results
Mybl2 gene products in pre-implantation blastocysts and
pluripotent stem cells
Previous studies have shown that B-Myb is present in mES cells,
is required for continued epiblast growth during the post-
implantation phase of mouse development, and is necessary for
the derivation of mES cell lines [14]. We have extended these
earlier studies and found that B-MYB proteins are present in pre-
implantation embryos at 2- and 4- cell stages, in the morula and in
early cavitation stage embryos (not shown). We also detect B-MYB
in both the inner cell mass and mural trophectoderm of pre-
implantation blastocysts (Figure 1A). Although it is unclear if B-
MYB is functional at these embryonic stages, its early expression
and presence in the developing trophectoderm suggest that it
might have a regulatory role prior to implantation.
By qRT-PCR, we determined that B-Myb transcripts are from
100- to .10,000-fold more abundant in mES, murine embryonic
germ (mEG), and murine embryonic carcinoma (mEC) cell lines
than in all other fetal and adult mouse cell lines and tissues
examined (Figure 1B). Transcripts to A-Myb and C-Myb were
detected in mES and mEG cells (Figure 1C), but at levels much
lower than those found in testes and Sca1
+ bone marrow cells,
respectively. In contrast, B-Myb was ,10- and 5-fold less
abundant in testes and Sca1
+ cells than were transcripts to A-
Myb and C-Myb, respectively (n$3 independent samples). The
relative abundance of myb family members in these tissues is
consistent with the expression data found in the Gene Expression
Atlas, thus confirming primer specificity and the presence of A-
and C-Myb transcripts in ES cells. Interestingly, the quantity of A-
Myb and B-Myb transcripts were similar in trophectoderm (TS)
cell lines. Finally, B-Myb transcripts were also prevalent in the
human ES cell line H1 and at levels much greater than in normal
human adult tissues like heart. Its abundance was, however, only
5–10-fold greater on average than that in HeLa cells, which has
relatively high levels of B-Myb (see http://symatlas.gnf.org/
SymAtlas/201710_at in NCI60 on U133A, gcRMA)(Figure 1D).
In mES cells, a band (spot) of 95 kDa was observed for B-MYB
on both one- and two-dimensional gel western blots (Figure 1E).
No signal for either A- or C-MYB could however be demonstrated
in any ES cell line (R1, D3) examined, thus confirming the
preponderance of B-MYB in mES cells. At the cellular level, B-
MYB immunostaining was predominantly nuclear and relatively
homogeneous in mES and in human ES cells (line H1) (Figure 1F).
Mitotic cells, however, had a unique staining pattern that was
characterized by dissociation of B-MYB and OCT4 from the
chromatin (Figure 1F, hBMYB and hOCT4). This latter finding
indicates that these transcription factors may be redistributed to
the extrachromosomal space during periods of mitosis.
Notably, induction of mES cell differentiation led to dynamic
changes in B-Myb RNA and protein expression, but the timing of
change depended on the model of differentiation. The first model
that we tested consisted of an aggregation technique where mES
cells were dissociated with trypsin and allowed to reaggregate to
form embryoid bodies (EB) in the absence of leukemia inhibitory
factor (LIF). With this model, B-Myb RNAs were significantly
reduced within 48–72 hours (See Figure 1B, R1 Cells), and this
reduction was slightly earlier than the decrease in Oct4 transcripts.
Separately, withdrawal of both fetal calf serum (FCS) and LIF
from non-aggregated mES cells led to a significant decrease in B-
Myb transcripts within 8 hours of withdrawal. This decrease was
transient, because within 24 hours, B-Myb transcripts returned to
control levels (Figure 1G). No significant change in Oct4
transcripts could however be demonstrated during this same time
course. At the cellular level, FCS and LIF withdrawal induced a
rapid decrease in B-MYB immunostaining in mouse ES cells (D3,
R1: Figure 1H). The reduction was particularly apparent in D3 ES
cells, where loss of staining was observed within 2 hours and prior
to any significant change in B-Myb RNA. The greatest reduction
in immunostaining was observed at 8 hours of differentiation, and
similar to the RNA data, the signal intensity returned to baseline
levels at $24 hours after FCS and LIF withdrawal. Moreover,
these dynamic and transient changes in B-MYB protein
abundance could be quantified by western. B-MYB proteins
significantly (p,0.05) decreased (relative to total protein) within 4
to 8 hours of FCS and LIF withdrawal, but after 24 hours, the
protein returned to levels observed in undifferentiated cells
(Figure 1I).
Knock-down of B-Myb
Since B-Myb was transiently down-regulated in mES cells with
differentiation, a short-hairpin RNA based technique was
employed to deplete B-Myb mRNAs to examine its function.
Five short-hairpin RNAs (shRNAs) were cloned into pSuper.puro
(Figure 2A, and Table 1) and transfected into E14 and D3 or
nucleofected into R1 and D3 ES cell lines. In pilot experiments, all
five shRNAs decreased the quantity of B-Myb in the E14 and D3
cells, but shRNA1 and 2 proved most effective. In this study, only
these latter two constructs were employed to knockdown B-Myb.
A non-targeting (NT) shRNA and empty vector (pSuper) were
employed as negative controls, and a shRNA to Oct4 was used as
a positive control.
Here, we present data from both lipofectamine-transfected (D3)
and nucleofected (R1) ES cells; however, identical expression data
were observed with transfected E14 and nucleofected R1 and D3
ES cells, which rules out any possibility of major variations in
cellular responses due to cell line variation or to the mode of
transfection. Following transfection, cells were cultivated in the
presence of FCS and LIF, prior to the selective addition of
puromycin to enrich for transfected cells. Relative to the NT
shRNA controls, cells transfected with control Oct4 shRNA
reduced endogenous Oct4 transcripts by .90% (data not shown),
while knock-down of B-Myb led to a significant reduction in
endogenous B-Myb transcripts by 60–70% (Figure 2B) and by
.90% in puromycin-selected cells (Figure 2C). None of the major
proteins observed on an amido black stained gel showed altered
expression and, more specifically, no change in Utf1 and Hdac
B-Myb in ES Cells
PLoS ONE | www.plosone.org 2 June 2008 | Volume 3 | Issue 6 | e2478Figure 1. Mybl2 gene products are abundant in pluripotent stem cells and are dynamically regulated during differentiation. A)
Representative immunostainings of pre-implantation mouse blastocysts. Immunostaining of B-MYB proteins was observed not only in the inner cell
mass (ICM) but also in the mural trophectoderm. Antibodies to NANOG were used to specifically mark cells of the ICM [42]. B) Summary qRT-PCR data
showing the relative abundance of B-Myb mRNA among cells and tissues. Data are expressed in heat map form, where color intensity (red) indicates
the relative abundance of B-Myb transcripts. Although relatively high expression is seen in proliferating MEFs and adult brain, transcripts are more
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of this shRNA-mediated knockdown.
After an overnight cultivation, nucleofected R1 mES cells
formed small dome-shaped colonies that consisted primarily of
small round cells with a relatively large nuclear to cytoplasmic
ratio (Figure 2D, insets in panels 1, 2, 4 and 5). The lipofectamine
treated cells however formed loosely aggregated, flattened cell
clusters. We attribute the morphological changes to differences
between the two protocols, but importantly and irrespective of the
technique, puromycin-resistant ES cells colonies transfected or
nucleofected with control vectors (pSuper, NT) remained relatively
compact and increased in size as a function of time (Figure 2D,
panels 1 and 2). Selected cells that had been transfected with a
shRNA against Oct4 however began to differentiate. Specifically,
most of the Oct4-deficient cells appeared relatively large and had
distinct cytoplasmic and nuclear regions (Figure 2D, panel 3).
Similarly, knockdown of B-Myb led to a modified colony
morphology, but one that was distinct from cells lacking Oct4
(Figure 2D, panels 4–6). First, the puromycin-resistant ES cells
lacking B-Myb were comprised primarily of small, and apparently
non-proliferating cell clusters. Second and within 48–72 hours of
transfection, a number of cells both within and around the cell
clusters began to exhibit characteristics of differentiated cells
(Figure 2D, panels 5 and 6, see arrows). These included the
formation of spindle shaped cells, and an increase in the
cytoplasmic to nuclear ratio. Most of the cells within a cluster/
colony, however, retained morphological traits consistent with
undifferentiated ES cells. Subsequently and at .72 hours post-
puromycin selection, numerous individual and small groups of
cells were present that showed distinct signs of differentiation
(finger-projections, low nuclear to cytoplasm ratio), vacuolization
and membrane blebbing (Figure 2E). Altogether, these data
suggest that B-Myb might play a role not only in mES cell
proliferation but also in the initiation of differentiation.
Loss of B-Myb inhibits proliferation, increases aneuploidy
and promotes mitotic spindle errors
To directly assess proliferation, shRNA nucleofected cells were
exposed to bromodeoxyuridine (BrdU) and incorporation of this
thymidine analog into unsynchronized R1 ES cells was quantified
by flow cytometry (Figure 3A). In these experiments, non-selected
ES cells were examined 48 hours after nucleofection, and
following pulse incorporation of BrdU (30-minutes) into newly
synthesized DNA to provide an estimate of the fraction of cells in
S-phase. The percentages of BrdU-labeled cells decreased in cells
transfected with shRNAs targeted to B-Myb relative to controls
(Figure 3B, p,0.001). At this time, the number of cells in G1,
determined by propidium iodine incorporation, did not differ
among any of the nucleofected groups, but a significant increase
and decrease, respectively in the number of cells in G2/M and S
phases were observed in B-Myb-deficient cells. Additionally, a
two-hour pulse produced a highly significant (p,0.001) and
unique pattern of BrdU incorporation, characterized by localized,
patchy or punctate staining. The percentage of cells (n$200) with
strong punctate or patchy staining ranged from 35% (pSuper, NT)
to 67% (shRNA1); whereas, those cells with a more diffuse or
relatively homogenously BrdU staining (containing discrete foci of
BrdU immunoreactivity equally distributed throughout the
nucleus) ranged from 65% in controls to 32% in knockdown
experiments (Figure 3C). This pattern of incorporation is
consistent with either changes in chromosome condensation,
similar to those observed in developing Drosophila eye [12] or,
alternatively, to altered cell cycle states in S phase.
Analysis of DNA content as a function of time revealed an even
more striking phenotype. Knockdown of B-Myb decreased the
number of G1 and S phase cells, increased the number of G2/M
cells, and significantly increased the number of cells with .4N
complement of chromosomes. Nucleofection alone, but not
lipofectamine-mediated transfections, increased the incidence of
cell aneuploidy in R1 cells from ,0.1% to 8–11%; however,
knockdown of B-Myb by either technique specifically led to either
tetraploidy (4N) or aneuploidy in ,20% of the mES cells (24 h,
Figure 4A). Within 48 hours, octoploidy (8N) was observed in 9.0
to 12.5% of cells lacking B-Myb (p,0.05, n=4), and within
72 hours, the incidence of octoploidy increased by 3-fold (NT
shRNA: 11.061.1%; shRNA1: 30.462.8%; shRNA2:28.363.7%;
n=4). At this time, 16N cells were also readily detectable (NT
shRNA: 0.1260.04%; shRNA1: 1.6960.44%; shRNA2:
1.7664.1% of viable cells, n=4)(72 h, Figure 4A), and
0.260.12% (n=3) of cells had a 32N complement of chromo-
somes. The latter was never observed in any of the controls.
The increased incidence of polyploidy was specifically due to B-
Myb knockdown and not a result of off-target effects, because
when cells were co-transfected with an expression vector
containing a full-length cDNA of B-Myb containing silent
mutations in the sequence specifically recognized by shRNA1
(Table 1), the number of G1/S phase cells increased by
10.763.1% and the number of 4N cells decreased by
10.161.7% relative to expression vectors containing wild-type B-
Myb. The number of polyploid cells generated with shRNA1 was
also reduced by 27.9%; however, when the expression vector
containing the silent mutation was nucleofected with shRNA2, no
rescue could be observed. The rescue of the shRNA1 phenotype
was however only partial, probably because knockdown of
endogenous B-Myb transcripts was temporally faster than the
expression of the rescue vector.
After 5–7 days of cultivation and following an initial puromycin
selection for 24 hours, almost none of the surviving, proliferating
cells retained 8N, 16N or 32N chromosomes. Instead, numerous
cells were aneuploid. This finding was confirmed both by flow
than 100-fold less than that seen in ES cells. Data for Oct4 and Nanog are included for comparison. C) Transcripts for B-Myb (100 bp), A-Myb (74 bp)
and C-Myb (76 bp) were detectable in ES cell lines by PCR, but B-Myb was the most abundant. D) Graphic representation of qRT-PCR analysis of B-
Myb transcripts in hES cells (H1), HeLa cells and adult human tissues (heart). Similar to mES cells, B-Myb is highly abundant in hES cells. E)
Representative one- and two-dimensional B-Myb immunoblot showing that anti-B-Myb antibodies react with a predicted protein of ,95 kDa. F) B-
MYB immunostaining is located in the nucleus, but during mitosis, it segregates away from chromatin, suggesting that its binding is dynamic. Data
are from mouse lines (R1, D3 and EG-1), where B-Myb immunstaining is shown green (FITC) and nuclear staining (Hoechst) is in blue; and from human
H1 ES cells, where immunostaining for B-Myb and Oct4 are shown in green (FITC), and nuclear staining is in red (TOPRO). A magnified view of human
ES cells showing the dissociation of B-Myb and Oct4 from the chromatin of mitotic cells is indicated by arrows. G) B-Myb transcripts are transiently
down-regulated when ES cells are induced to differentiate by serum (FCS) and LIF withdrawal. H) B-MYB immunostaining is transiently decreased by
FCS and LIF withdrwal in D3 and R1 (inset) ES cells. I) The transient decrease in B-MYB proteins observed through immunostaining was quantitatively
confirmed by western blotting. In this image, an expanded view of the two-dimensional westerns shown in Figure 1E (dashed boxed region) is
shown. When normalized to total protein, the transient loss of B-MYB (two-spots) was highly reproducible (p,0.05) and similar to but more rapid
than that observed for B-Myb RNA. Bar=50 mm. *p,0.05 relative undifferentiated ES cells.
doi:10.1371/journal.pone.0002478.g001
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PLoS ONE | www.plosone.org 4 June 2008 | Volume 3 | Issue 6 | e2478Figure 2. shRNAs specifically knockdown B-Myb in ES cells. A) Line drawing of B-Myb and location of silencing shRNAs tested in this study. B)
Endogenous B-Myb mRNAs are effectively reduced following cell transfections with shRNAs against B-Myb (shRNA1, shRNA2), but no reduction in B-
Myb could be demonstrated with the negative controls [non-targeting (NT) shRNAs or empty vector (pSuper.puro)]. C) By western, B-MYB proteins
were reduced in ES cells by ,50–70% following knockdown with shRNA1 or shRNA2, but when selected with puromycin, reductions in B-MYB of
.90% were routinely seen. Loading controls indicate that the shRNAs were specific for B-Myb. D) Representative cell morphologies of R1 and D3 mES
cells after transfection. The insets in panels 1, 2, 4 and 5 correspond to cell morphologies of R1 cells 24 hours after nucleofection and prior to
B-Myb in ES Cells
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.4N peaks) relative to an internal control (Figure 4B)] and by
chromosome spreads, where additional chromosome fragments
were observed. Interestingly, the aneuploid cell population had
many of the growth characteristics of karyotypically normal R1 ES
cells i.e., the cells proliferated quickly, required passaging every
24–36 hours, and had similar colony morphologies. OCT4,
NANOG and SOX2 proteins were also present, and when
induced to differentiate, diverse cell morphologies were observed,
suggesting that these aneuploid cells remained multipotent. The
karyotype of some surviving cells was however abnormal
(aneuploidy), leading us to conclude that these cells may no longer
be viable germ-line transmissible mES cells.
To elucidate mechanisms underlying these chromosomal
abnormalities, we assessed the incidence of sister chromatid
exchanges (SCEs), analyzed c-H2AX histone immunoreactivity (as
an index of DNA strand breaks), and determined the number of
DNA events associated with fragmentation, fusion, and breakage
(abnormalities/chromosome). The incidence of SCEs and the
number of abnormalities/chromosome did not differ among the
groups (Table 2), and we could not demonstrate any increase in c-
H2AX histone immunostaining among any of the B-Myb
knockdown groups relative to controls (n=4). The most obvious
defects in cells lacking B-Myb were numeric changes in
chromosomes (Figure 4C and Table 3), which could be due to
errors in spindle formation/function or chromosomal segregation
during the M phase of the cell cycle. To examine these latter
possibilities, R1 ES cells were immunostained with antibodies
against a- and c-tubulin, which respectively, are the major
components of spindles and centrioles found in the mitotic
organizing regions (centrosomes) of dividing cells. In these
experiments, cells in prophase, metaphase, anaphase and
telophase were readily observed in control (pSuper, NT) cells,
and the majority of mitotic cells (,80–90%) contained two
centrosomes located at opposite poles in the cell. Normal spindle
formation was also observed between mitotic organizing regions
and chromosomes (NT, Figure 4D). In contrast, it was difficult to
find any B-Myb-deficient cells in anaphase or telophase, and
mitotic cells had significantly fewer bipolar centrosomes than
controls (Figure 4E, p,0.001). In fact, over 35% of the mitotic
cells contained monopolar spindles comprised of either a single
centrosome or grouped centrosomes, and spindle abnormalities
were significantly increased (B-Myb shRNA1, Figure 4D, 4E).
Loss of B-Myb promotes differentiation and apoptosis
Because FCS and LIF withdrawal are associated with a
transient loss of B-Myb (Figures 1G and 1H) and knockdown of
B-Myb led to morphological changes in mES cells consistent with
differentiation (Figure 2D), we went on to assess whether knock-
down of this transription factor could promote differentiation,
even under cultivation conditions (+LIF and +FCS) that normally
maintain pluripotency. For this, we quantified RNAs encoding
early markers of differentiation (CoupTF and FGF5), and markers
specific for ectoderm (Sox1, Nestin), endoderm (Sox17, Gata4),
mesoderm (Brachyury), and trophectoderm (Cdx2, Hand1)
lineages (Figure 5A). Under control conditions, these markers
were either undetectable or at the limits of PCR detection, but
within 48 hours of knocking down B-Myb, CoupTF and FGF5
were significantly up-regulated, as were both trophectoderm
markers (p,0.05, n=4). Definitive endoderm markers Sox17
and Gata4 (not shown) mRNAs were upregulated; however,
brachyury was undetectable in cells at all time points examined,
and the neuro-ectoderm markers gave variable results. A non-
significant decrease in Hdac2 was also observed. The up-
regulation of some differentiation markers (COUPTF, SOX17,
and HAND1) was furthermore confirmed by western (Figure 5B),
but their presence was only observed at .48 hours post-
nucleofection.
Importantly, a significant decrease in pou5f1 and sox2 gene
products (RNA and protein)(Figures 5C, 5D) was observed within
24–48 hours of B-Myb knock-down, while transient over-expres-
sion of B-MYB increased endogenous OCT4 and SOX2 proteins
by 18–30% (p,0.05, Figure 5E, 5F). In contrast, no consistent
decrease in NANOG could be demonstrated after knock-down of
B-Myb except in puromycin- selected cells between 48 and
72 hours after transfection. Over-expression of B-Myb did not
produce a significant increase in NANOG. These data in
particular suggest that the genes encoding Sox2 and Oct4, but
not Nanog, might be targets of B-MYB regulation.
To further validate the findings of differentiation, independent
of gene markers, we examined the viability of the transfected cells
and determined whether apoptosis, which is generally elevated
with differentiation, was altered. For this we employed the the
water-soluble tetrazolium (WST)-1 assay, an indicator of both
mitochondrial function in living cells and cell viability. Using this
assay, we found a significant segregation and loss of viability in
mES cells transfected with B-Myb shRNAs (p,0.05, Figure 5G).
Because no increase in apoptosis, measured either by annexin V (a
Ca
2+-dependent, phospholipid binding protein with a high affinity
for phosphatidylserine) and propidium iodine (a nuclear stain)
staining (data analyzed by flow cytometry, not shown) or by DNA
fragmentation (i.e., DNA laddering), could be demonstrated at 24
or 48 hours post-nucleofection, the loss of viability appeared to be
wholly due to reduced cell proliferation; however, at 72 hours
puromycin selection. D3 cells are also shown 48 hours (Panels 1–5) and 72 hours (Panel 6) after lipofection and puromycin selection. The shRNAs
employed in each set of experiments are indicated in the figure, and consisted of negative controls (Non-targeting, NT or pSuper), a positive control
(shRNA specific for Oct4) and experimentals (shRNA1 and 2, which are specific for B-Myb). Knockdown of B-Myb effectively reduced colony sizes
(Panels 4, 5) and led to cells with a more differentiated phenotype (Panels 5 and 6, see arrows). In panel 6, a non-targeting (NT) control is included for
comparisons. Size bar=50 mm. E) Phase image of R1 ES cells at 72-hours post nucleofection. Cells lacking B-Myb (shRNA1) and selected by puromycin
for 48 hours showed distinct signs of differentiation, vacuolization and membrane blebbing. Bar=25 mm.
doi:10.1371/journal.pone.0002478.g002
Table 1. shRNA sequences
shRNA Construct Target Sequence Position
B-Myb RNA1 GGTGCGACCTGAGTAAATT 1159–1177
B-Myb RNA2 GAAGAGCACGCCTGTCAAA 1526–1544
B-Myb RNA3 GTCTCTGGCTCTCGACATT 1958–1976
B-Myb RNA4 GTAACAGCCTGCTCAACCA 2086–2104
B-Myb RNA5 GGTGTGGGGTAAGGTTAAA 2354–2372
NT RNA GTAAGGGAGATGAGGCAAA
Gene-specific regions for RNA interference were designed as described in the
text and double stranded oligonucleotide cassettes were cloned into
pSUPER.puro (Oligoengine) after BLAST analysis to ensure against sequence
similarity with other genes. Positions are based on |NM008652.2| Mus musculus
myeloblastosis oncogene-like 2 (Mybl2), mRNA. NT- non-targeting.
doi:10.1371/journal.pone.0002478.t001
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programmed cell death was readily detectable (n=3 independent
preparations). The DNA laddering was caspase dependent, and it
could be fully inhibited by addition of 40 mmol/L Z-VAD-FMK
(carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylke-
tone) a cell-permeant pan caspase inhibitor (Figure 5H). More-
over, activated caspase 3 was observed at .48 hours in those cells
nucleofected with shRNA1 (data not shown); however, activated
caspase 3 could not be detected in controls (pSuper, NT) at any
time point examined. Importantly, the increase in DNA laddering
and in caspase 3 was only significantly increased in cells following
knock down of B-Myb (p,0.05).
B-Myb modulates the pou5f1 gene promoter
Having determined that alterations in B-Myb led to corre-
sponding changes in OCT4 protein abundance, the promoter
region of the pou5f1 gene was examined to identify possible MYB
binding sites. In mouse, six putative mybl2 binding sites (consensus
and non-consensus) were identified with software from Genomatix
(http://www.genomatix.de/). Consensus binding sites correspond-
ed to sequences at positions –295 (CAACaG), -799 (-CAACgG), -
1454 (CAACaG), and –2251 (TAACtG). To determine if any of
these sites might bind B-MYB, chromosomal immunoprecipitation
(ChIP) assays were performed with DNA extracts from mES (R1)
cells. Since B-MYB had previously been shown to bind to the myc
promoter, it was employed as a positive control [16,17]; while, IgG
antibodies were employed as a negative control. Following
immunoprecipitation with an antibody to B-MYB, an amplifica-
tion product was observed both from the myc promoter and from
the pou5f1 gene promoter (Figure 6A); however, no amplification
product could be observed following immunoprecipitation with
IgG. Moreover, differentiation of ES cells by withdrawal of FCS
and LIF led to a significant decrease in the SYBR Green signal
observed by qRT-PCR from the pou5f1 gene promoter following
B-MYB immunoprecipitation (Figure 6B, 6C). Since these results
are consistent with the differentiation-associated transient loss of
B-MYB in ES cells shown in Figures 1H and 1I, these data
confirm the specificity of these assays and show that B-Myb
dynamically binds to the pou5f1 gene promoter in ES cells.
Next, we employed the mouse nanog and human Oct4
promoters in transient transfection assays of murine ES cell lines
(D3, R1) to determine whether B-MYB could directly regulate the
transcriptional activity of pluripotency genes. In these experiments,
knockdown of B-Myb significantly decreased Oct4 promoter
Figure 3. BrdU incorporation into R1 ES cells. A) Representative flow cytometry data of nucleofected cells that were cultivated for 24 hours,
pulse labelled with BrdU for 30 minutes and immunostained with an antibody specific for BrdU. FITC fluorescence of BrdU stained cells is shown in
the boxed region (i.e., S phase cells), and the arrow points to the region of the histogram corresponding to cells in G0/G1. B) Averaged data showing
the number of cells in S phase decreased following knockdown of B-Myb (n=3, *p,0.05 relative to NT controls). C) Down-regulation of B-Myb leads
to a defect in BrdU incorporation during S phase. Immunostained control cells (NT shRNA or pSuper) that incorporated BrdU for 2 hours had a
relatively homogeneous but cloudy pattern of staining; whereas, cells lacking B-Myb (shRNA1) displayed a unique pattern characterized by punctate
and/or patchy staining (white arrow, p,0.001). The inset (red arrow) shows one group of cells that appears to have inappropriate chromosomal
structure. Bar=20 mm.
doi:10.1371/journal.pone.0002478.g003
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PLoS ONE | www.plosone.org 7 June 2008 | Volume 3 | Issue 6 | e2478Figure 4. DNA analysis of R1 ES cells. A) DNA content was measured by flow cytometry in non-synchronized ES cells that had been fixed and
stained with propidium iodine following nucleofection with shRNA. At 24 hours after nucleofection with shRNA1 and 2, the number of cells in S
phase decreased concomitant with an increase in the number of cells in G2/M relative to controls. At 48 hours, knockdown of B-Myb led to increased
octoploidy (8N), and the incidence of octoploidy was increased further at 72 hours (p,0.05). At this time, cells with a 16N and 32N (not shown)
complement of DNA were also detectable (see arrows in the inset, Logscale). B) In these experiments, ES cells were transfected with either a NT
shRNA (black line) or shRNA1 and selected by puromycin for 24 hours. Within 96 hours, the selected cells began to recover and proliferate, and
within one week, cells transfected with shRNA1 demonstrated a rightward shift in the cell’s DNA content, indicating that these surviving and
proliferating cells were karyotypically abnormal (i.e., aneuploid). C) Metaphase chromosome spreads after labelling in the presence of BrdU for
B-Myb in ES Cells
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Nanog promoter activity did not significantly differ among any of
the experimental groups (i.e, NT, pSuper, shRNA1 and shRNA2).
In contrast, shRNA knockdown of endogenous Oct4 transcripts
significantly reduced the activities of both the hOct4 and Nanog
promoters by ,70 and 80%, respectively (Figure 6D), confirming
that effects of B-Myb were specific to the hOct4 promoter.
Similar to mouse, the human Oct4 promoter sequence
contained 6 putative Myb binding sites [position: -233 (CAACtG),
-787 (CAACaG), -1046 (TAACaG), -1239 (non-consensus:
AACGgG) -1898 (CAACgG) and –2378 (TAACtG)]; however,
only one of these, at position –233, was located within the
proximal promoter near a consensus sequence present in the
mouse gene. An electrophoretic mobility shift assay (EMSA) was
therefore employed to determine if B-MYB could bind to this site.
For comparative purposes, a consensus MYB-binding sequence
from the bcl2 gene was used as a positive control [18]. In these
experiments, double stranded oligonucleotide cassettes were
incubated with nuclear extracts from HeLa cells or mouse R1
cells. The positive controls showed protein binding, and two DNA-
protein complexes (a and b) were identified with HeLa cell nuclear
extracts (Figure 6E), however, a single higher molecular weight
complex was observed with extracts from R1 ES cells, suggesting
that the transcriptional complexes differed between these two cell
lines. The addition of anti-B-MYB antibodies resulted in
formation of a complex in mouse with a lower mobility, and in
HeLa cells, most but not all of complex b (supershift, ss) showed
decreased mobility. Complex a did not show any change in
mobility and was therefore considered non-specific. The specificity
of these protein-DNA complexes for B-Myb was further verified
by an oligonucleotide cassette containing base pair changes within
the putative MYB-binding site, which failed to form DNA
complexes in either R1 or HeLa cells, and by addition of a 200-
fold molar excess of unlabeled competitor oligonucleotide.
To determine whether the myb-binding site was functional,
pluripotent murine R1 ES, P19 EC and non-pluripotent human
embryonic kidney 293T cells were transfected with native and
mutant hOct4-Luc constructs together with either a B-Myb over-
expressing vector under the control of the phosphoglycerate kinase
promoter or an empty vector. All luciferase data are reported
relative to the empty vector and after normalization to Renilla
luciferase activity. In both R1 ES and P19 EC cells, transient over-
expression of B-MYB led to an increase in hOct4-Luciferase
activity (Figure 6F). No significant increase in luciferase activity
could be demonstrated in P19 cells relative to controls, but an
,50% decrease in luciferase activity was observed in R1 ES cells
(Figure 6G), with the mutant constructs relative to controls. These
data suggested differential gene regulation between ES and EC
cells, consistent with what is known about the Oct4 promoter [19].
To rule out any possible effects associated with endogenous
pluripotency transcription factors (i.e., Oct4 or Sox2) present in ES
and EC cells, 293T cells were transfected with hOct4-Luc constructs.
In these experiments, normalized promoter activities of mutant and
wild-type constructs were much less in 293T cells than in ES cells
(p,0.05), and no difference was observed between 293T cells co-
tranfected with either the mutant or wildtype hOct4-promoter and
the empty parental vector. Over-expression of B-Myb, however,
selectively enhanced wildtype hOct4-luciferase activity by .3–5-fold
(Figure 6H). Unexpectedly, the mutant hOct-4-Luc constructs also
showed an increase of ,1.5–2-fold, suggesting that another binding
site on this promoter might be regulated by B-MYB. The increase
observed in the mutant was however significantly less than that
elicited by the wildtype hOct4 promoter sequence, leading us to
conclude that the trans-activation potential of the human Oct4
promoter by B-MYB is elicited, at least in part, through the MYB-
binding site located in the proximal promoter of this gene.
Discussion
In the present study, we show that knockdown of B-MYB in
mES cells decreases proliferation, cell viability and colony size,
,24 hours and counterstaining with Giemsa. Sister chromatin exchanges (SCE) (shown by the arrows) were scored each time a color switch between
dark or light sister chromatids occurred. In this study, no chromosomal abnormalities other than polyploidy or aneuploidy could be identified in any
of the cells examined. D) Representative mitotic cells stained with DAPI (blue), a-tubulin (green) and c-tubulin (red) are shown. Control (NT) mitotic
cells are shown in metaphase and telophase with normal biopolar centrosomes and normal mitotic spindles. In cells lacking B-Myb, mitotic spindle
and centrosome defects were readily observed. White arrows indicate cells with monopolar or multipolar centrosomes; whereas, red arrows show
abnormal spindle formations. E) Graphic representation of the number of monopolar, bipolar and multipolar centrosomes for each type of
nucleofected cell. *p,0.001 relative to NT controls. Bar=10 mm.
doi:10.1371/journal.pone.0002478.g004
Table 2. Frequency of SCE and chromosome abnormalities
Sample I.D.
Total no.
Chromosomes SCE (SCE/Chr)
Chromosomal fragment, fusion,
breakage (abnormalities/Chr) Metaphases
pSuper 2915 872 (0.299) 10 (0.003) 69
B-Myb shRNA1 2847 1090 (0.382) 7 (0.002) 67
NT shRNA 1172 468 (0.399) 0 (0) 39
A Sister Chromatin Exchange (SCE) was scored each time a color switch between dark or light sister chromatids occurred, and chromosomal aberrations, including
chromosomal breakage and fragmentation were analyzed was assessed as previously described [40]. NT- non-targeting.
doi:10.1371/journal.pone.0002478.t002
Table 3. Frequency of polyploidy
Sample I.D. Total metaphases polyploidy
pSuper 89 3 (3.3%)
B-Myb shRNA 86 12 (14%)
NT shRNA 48 2 (4.1%)
The frequency of polyploidy was determined from the data gathered in the
generation of Table 2.
doi:10.1371/journal.pone.0002478.t003
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latter is associated with centrosome and mitotic spindle defects,
which lead to a high incidence of polyploidy that results either in
programmed cell death or sustained aneuploidy (see Figure 7). The
activation of apoptosis, however, only occurs after the induction of
differentiation and subsequent to the loss of pluripotency factors.
Iwai et al. previously found that a dominant-negative interfering
form of C-Myb (dnMyb) led to an accumulation of mES cells in the
G1 phase of the cell cycle as well as to changes in proteins associated
with cell adhesion [15]. They showed that activation of dnMyb did
not induce the expression of any germ layer differentiation markers,
even though E-Cadherin, a marker of epiblast, was down-regulated;
and they did not observe any apoptosis. One possible explanation
for the disparity between their study and ours may be experimental.
In the present study, we employed shRNAs and puromycin
selection to examine cells that had a significant and specific
reduction in B-MYB proteins. In contrast, Iwai et al. had assumed,
because of the conserved protein homologies and consensus binding
sequences, that the dominant-negative interfering form of C-Myb
would inhibit the activity of B-Myb in ES cells; however, important
differences are now known to exist between these two transcription
factors. First, only B-Myb, and neither A- nor C-Myb, can rescue
the phenotype of Dm-Myb deficient Drosophila mutants in
complementation experiments [6]. Second, transactivation of genes
by myb family members varies considerably depending on the cell
type and promoter context [1], and in the absence of co-factors, for
example, B-MYB is a relatively poor trans-activator of some gene
promoters when compared with either C-MYB or A-MYB. Third,
phylogenetic analyses imply that the A-myb and C-myb genes arose
from a B-Myb/Dm-Myb-like ancestor by two gene duplication
events that included the acquisition of a unique transcriptional
activation domain [6]. It is therefore likely that knockdown of B-
Myb would have different effects on either transcription and/or
replication than those exhibited by a dominant-negative interfering
form of C-Myb.
Our results also provide an additional explanation for the causes
of embryonic lethality reported by Tanaka et al. [14]. Develop-
mentally and after implantation on day 4, the early murine
epiblast begins to expand and differentiate to form columnar
epithelium. This transition is accompanied by increased cell
proliferation and expansion of pluripotent cells from ,25 to ,660
cells by 6.5 dpc [20]. Although the embryonic lethality of B-Myb-
knockout mice at 4.5–6.5 dpc has generally been attributed to
defects in proliferation, we show that the primary cell cycle defects
in mES cells are due to delays in G2/M that are associated with
mitotic spindle defects and polyploidy. We also show that loss of B-
Myb in LIF-cultivated ES cells leads to an up-regulation of
differentiation markers followed by an activation of caspase-
mediated DNA fragmentation. Since mES cell differentiation is
associated with the establishment of robust cell cycle checkpoint
controls that strongly promote apoptosis of polyploid cells [21], the
loss of ICM observed by Tanaka et al. may have resulted not only
from a proliferation defect but also from programmed cell death
that is activated in response to differentiation and the formation of
columnar epithelium.
Moreover, the data presented in the current paper are
consistent with B-Myb being a general regulator of S phase
progression. In fact, we show highly significant and inappropriate
BrdU incorporation into chromatin (Figure 3C), which indicates
either a potential replication defect or problems with chromosome
condensation. Similarly, Manak et al. have shown in Drosopholia
that the primary function of B-MYB is associated with DNA
replication, and not in gene regulation [11,12]; however, we also
show specific defects in mitotic progression and spindle formation
that are similar to those reported in zebrafish. Shepard et al.
showed that zebrafish mutants lacking crb (the zebrafish B-myb
equivalent) had enhanced chromosomal instability and that
injection of cyclin B RNA partially restored the genomic integrity
of Myb mutants [13]. Consistent with their findings, cyclin B1
transcripts are decreased in ES cells following knockdown of B-
Myb (unpublished data), and since cyclin B is activated in late S
phase by B-Myb, it is likely that the defects in spindle formation
and centrosomes observed in ES cells lacking B-Myb are elicitied,
at least in part, through control of cyclin gene expression during
progression through S phase.
Importantly, B-MYB specifically binds to a proximal sequence
in the endogenous mouse pou5f1 promoter, and altered expression
of B-Myb in mES cells leads to coordinate changes in endogenous
Oct4 expression. Although the changes in endogenous Oct4
expression are modest, studies with the human Oct4 gene
promoter show that the effects of B-Myb on this gene are
unambiguous. Specifically, point mutations to a proximal myb-
binding site of the human Oct4 promoter inhibited the trans-
activating potential of this transcription factor both in pluripotent
stem and 293T cells; however, the inhibition in 293T cells, was
only partial, suggesting that another binding site or formation of
an unique transcriptional complex regulated by B-MYB may be
involved in the control of pou5f1 gene activity. Some differences in
activity were also noted between R1 ES and P19 EC cells (see
Figure 6D), and since the Oct4 promoter depends on distal and
proximal enhancer elements to control pre- (ES cell) and post- (EC
cell) implantation expression, respectively, a detailed promoter
analysis will be required to elucidate how pou5f1 promoter activity
is regulated by B-MYB [19]. It is likely, however, that the effects of
B-Myb on the pou5f1 gene promoter will be primarily modulatory.
The myb-binding site that was mutated in this study is not present
within any of the four conserved regions of homology or enhancer
regions known to be critical to its regulation [19]. Over-expression
Figure 5. Loss of B-Myb promotes differentiation and apoptosis. A) Relative mRNA levels were determined by qRT-PCR following knockdown
of B-Myb. In these experiments, markers of differentiation (CoupTf, Fgf5, Sox1, Nestin, Sox17, Hdac2, Cdx2, Hand1) were either absent or at the limits
of detection in undifferentiated cells, but following knockdown of B-Myb, several markers (CoupTf, Fgf5, Sox17, Cdx2 and Hand1) showed significant
(p,0.05) changes in expression. B) Western analysis of Sox17, CoupTf and Hand1 confirmed that loss of B-Myb was associated with an up-regulation
in markers of differentiation. C) Knockdown of B-Myb led to a significant reduction in transcripts encoding pluripotency markers Oct4 and Sox2 within
48 hours, but not in UTF1. A significant reduction in Nanog was generally only observed .72 hours after loss of B-Myb. All data were determined by
qRT-PCR. D) Knockdown of B-Myb also led to a reduction in OCT4 and SOX2 proteins at 48 hours post-nucleofection that could be detected by
western (n=3). E) Over-expression of B-MYB, relative to the parental vector control, led to increased OCT4 and SOX2 protein abundance. F) Summary
data for OCT4 and SOX2 expression in mES cells following over-expression of B-Myb (PGK-B-Myb). In these experiments, the over-expression of B-Myb
was transient, as were the increases in Oct4 and Sox2. G) The WST-1 assay shows a significant segregation in the absorbance of the colormetric dye in
D3 cells transfected with B-Myb shRNAs relative to controls. This segregation indicates a loss in cell viability in mES cells lacking B-Myb (p,0.05). H)
Loss of B-Myb promotes apoptosis, but only 72 hours after nucleofection. No increased genomic DNA fragmentation (apoptosis) was ever observed
at 24 or 48 hours following knockdown. Importantly, the DNA fragmentation could be inhibited by Z-VAD-FMK, a pan-caspase inhibitor, indicating
that the observed DNA laddering was due to active caspases. *p,0.05 relative to NT controls (n=3).
doi:10.1371/journal.pone.0002478.g005
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extracts from R1 mES cells. In these experiments, PCR amplifications were performed with total input DNA (positive control without
immunoprecipitation) and following immunoprecipitation (IP) with antibodies to either B-MYB or to rabbit IgG (as a negative control). Amplifications
of immunoprecipitated DNA were analyzed by agarose gel electrophoresis, and Myc was employed as a positive control. The presence of an
amplification product in the anti-B-Myb immunoprecipitated DNA indicates that B-Myb binds a proximal region of the mouse pou5f1 promoter. B) In
the second set of experiments, which were evaluated by qRT-PCR, we find that B-MYB dynamically binds to the endogenous pou5f1 promoter region.
In undifferentiated cells, an amplification signal 10–15-fold above that seen in the IgG control is observed; however, this signal is reduced to only 2–4
fold above the IgG control following withdrawal of LIF and FCS. All qRT-PCR amplifications were performed using SYBR Green with primers located 59
and 39 to the putative binding site. C) The dynamic decrease in chromatin binding of B-Myb to the pou5f1 gene promoter in mES cells cultivated
either in the presence or absence of FCS and LIF is illustrated graphically (p,0.05, n=3). D) To test the transactivation potential of B-MYB on
pluripotency genes, human (h)Oct4 and mouse Nanog promoter constructs containing a Luciferase reporter were used in transient transfection
assays. In these experiments, D3 cells were transfected with the constructs as indicated. The positive control Oct4 shRNA reduced the promoter
activities of both the hOct4 and mouse Nanog promoters; however, knockdown of B-Myb only reduced the promoter activity of the hOct4 promoter.
*p,0.05 relative to NT controls. E) To determine if B-MYB proteins could bind to the human Oct4 promoter, EMSAs were performed with HeLa cell
nucleoextracts (lanes 1–6) and R1 nucleoextracts. Positive control cassettes revealed two DNA-protein complexes (a and b) in HeLA cell nuclear
extracts and a single higher molecular weight complex in extracts from R1 ES cells. Addition of anti-B-MYB antibodies resulted in formation of a
complex in mouse with a lower mobility, and in HeLa cells, most but not all of complex b (supershift, ss) showed decreased mobility. Complex a did
not show any change in mobility and was therefore considered non-specific. An oligonucleotide cassette containing base pair changes within the
putative MYB-binding site failed to form DNA complexes in either R1 or HeLa cells, and the addition of a 200-fold molar excess of unlabeled
competitor oligonucleotide also led to a loss of signal. [Data are presented as follows: Lane 1: biotin-end labeled 24 bp DNA duplexes containing the
putative MYB-binding site located at position –223 of the hOct4 promoter. Lane 2: same as in Lane 1, but with the addition of anti-B-MYB antibodies.
Lane 3: biotin-end labeled 27 bp DNA B-Myb consensus sequences (positive controls). Lane 4: as Lane 3 plus anti-B-MYB antibodies. Lane 5: as Lane 1,
with non-labeled competitor DNA (200-fold). Lane 6: as Lane 1, with biotin-labeled DNA duplexes containing a mutated Myb binding sequence. R1:
biotin-end labeled 24 bp DNA duplexes containing the putative MYB-binding site located at position –223 of the hOct4 promoter and incubated with
nucleoextracts from R1 ES cells. Note that the DNA protein complex migrates more slowly than those observed with HeLa cells.] Oligonucleotide
sequences are described under Methods. F) A 2.8 kb hOct4 promoter-Luciferase construct was employed to assess the ability of B-MYB to directly
regulate its activity in vitro. In these experiments, R1 ES and P19 EC cells were co-transfected with plasmids containing a 2.8 kb hOct4 promoter-
Luciferase construct promoter and either a CMV promoter driven mouse B-Myb construct or empty vector. Relative luciferase activity, normalized to
Renilla luciferase and the empty vector controls, was taken as a measure of transcriptional activity. G) R1 ES and P19 EC cells were co-transfected with
either a CMV promoter driven mouse B-Myb construct or empty vector, but in this case, the 2.8 kb hOct4 promoter-Luciferase construct contained a
mutation in the putative Myb-binding site (position –223) that had been putatively identified from a genomic analysis with Genomatix software. H)
To exclude the possibility that pluripotency factors present in ES and EC cells might have affected the relative luciferase activities, wildtype and
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following LIF withdrawal [22]. It is however possible that some
fate decisions (i.e., Cdx2, Hand1 expression) may be mediated, in
part, through B-Myb mediated changes in Oct4 expression,
particularly since a modest change in OCT4 can promote ES cell
differentiation to trophectoderm [23] or specification to a cardiac
lineage [24]. Because several pluripotency-associated genes [Fgf4,
c-Myc, Bcl-2] are also regulated by B-Myb in non-ES cells [16–
18,25–28], their potential effects secondary to changes in B-Myb
function on fate decisions, specification and differentiation of ES
cells can not be ignored. Future experiments will be required to
deal with these possibilities.
In conclusion, B-Myb is required for maintenance of the
pluripotent state, and its expression and function are critical to and
potentially a determining factor of murine ES cell fate decisions in
vitro. Appropriate levels of B-Myb are required to maintain
chromosomal integrity and cellular euploidy, and any dysregula-
tion in the expression or function of B-Myb promotes differenti-
ation and/or aneuploidy that can result in apoptosis (Figure 7). B-
Myb is therefore critical not only for mouse embryonic
development, but also for a normal karyotype and maintenance
of viable embryonic, and potentially, all proliferating somatic stem
cells. Because human ES cells are susceptible to chromosomal
rearrangements and karyotypic abnormalities, the data generated
in this study suggest one possible mechanism that may account for
some of this instability.
Materials and Methods
Cell Culture
Mouse and Human cell lines. D3, R1, E14 murine (m)ES
cell lines, H1 (h)ES (WiCell, Agreement No: 05-W102, NIH code
WA01) cells, P19 EC and EG-1 cell lines were cultivated on feeder
layers of mouse embryonic fibroblasts (MEFs) or under feeder free
conditions as previously described [29–31]. HeLa and 293T cells
(ATCC) were grown in DMEM supplemented with 10% fetal
bovine serum (Invitrogen), and Sca1-positive cells, lineage-
negative cells, were isolated from bone marrow (BM) of CD-1
mutant hOct4-Luc constructs were co-transfected into human kidney 293T cells. In these experiments, the relative activity of the hOct4-Luc
constructs was much less than that observed in R1 or P19 cells; however, when co-tranfected with the CMV-B-Myb vector, the relative luciferase
activity increased significantly relative to empty vector controls. The increase was however significantly less when the mutant hOct4-Luc construct
was employed in 293T cells. In summary, data from the luciferase assays (F, G and H) indicate that B-Myb can transactivate the hOCT promoter in
vitro, and that its actions are mediated in part through protein binding to the proximal Myb-binding site located at position –223. * p,0.05 relative to
either the native or mutant hOct4 promoter-Luciferase+empty vector. #p,0.05 relative to mutant hOct4-Luciferase+B-Myb (PGK-BMYB).
doi:10.1371/journal.pone.0002478.g006
Figure 7. Proposed functions of B-Myb in ES cells. A) Under normal conditions, high levels of endogenous B-Myb promote proliferation
through coordination of events in S phase and appropriate transit through G2/M. It also modulates Oct4 expression to help maintain the
undifferentiated and pluripotent state of ES cells. B) The primary effect of reduced levels of B-Myb is the generation of polyploid and aneuploid cells
due to a loss of normal cell cycle progression through G2/M and spindle defects. Loss of B-Myb also causes a reduction in Oct4 expression and ES cell
differentiation. Because differentiated cells have tight checkpoint controls that are capable of recognizing chromosomal abnormalities and activating
apoptosis, this may represent a control mechanism necessary to maintain chromosome fidelity during early embryo development. Many of the
surviving mES cells that were transiently deficient in B-Myb do not undergo apoptosis. Instead some of these cells become aneuploid, and can no
longer be considered as authentic ES cells. Gene products in parentheses represent additional but putative targets of B-Myb regulation.
doi:10.1371/journal.pone.0002478.g007
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Technologies, Cat No 17036).
RNA Preparation, Reverse Transcription, and Real-Time
PCR Analysis
RNA was extracted, treated with DNAse, and cDNA
synthesized using High Capacity cDNA Archive Kit (Applied
Biosystems). Real-time PCR reactions were performed with an
ABI PRISM 7900HT Sequence Detector System (PE Applied
Biosystems) using a SYBR Green protocol or TaqMan protocols
with the core reagent kit and either SYBR Green PCR Master
Mix (Applied Biosystems) or PlatinumH SYBRH Green qPCR
SuperMix (Invitrogen) [32]. RNA from TS cells was kindly
provided by M. Ko (NIA, Baltimore). Primers were designed with
Primer Express 2.0 software (Table 4) or pre-designed by Applied
Biosystems (TaqManH Gene Expression Assays).
Protein Analysis
Westerns were performed as described [32,33], and membranes
probed with primary antibodies to rabbit B-myb (Abcam and
Santa Cruz), rabbit Nanog, rabbit cyclin B1 (Abcam), rabbit A-
myb, rabbit C-Myb, goat Cdx2, rabbit CoupTF, rabbit eHand,
goat Fgf5, goat Sox1 and goat Sox17 (Santa Cruz), rabbit active
Caspase-3 (Cell Signal), and rabbit Oct4 (Chemicon). Blots were
re-probed with HRP conjugated goat anti-rabbit IgG(H+L)
(Zymed) or donkey anti-goat IgG(H+L) (Santa Cruz), and
horseradish peroxidase was detected using Pierce Super Signal
ECL substrate kit and chemiluminescence captured on Kodak
BioMax Light film. Immunostaining of mouse ES cells was
performed as described [29,32].
Plasmids containing shRNAs and B-Myb
Nineteen-base-pair gene-specific regions for RNA interference
were designed based on algorithm rules by [34,35]. Oligonucle-
otides were cloned into pSUPER.puro (Oligoengine) after BLAST
analysis to ensure against sequence similarity with other genes.
[36].
B-Myb was amplified using primers GAGCAGCCT-
GAGTCCTGACC and AGACCCTGATAGGGTTCCTTCT
found at positions 287 and +2367, respectively of Mybl2 sequence
NM008652. The cDNA was cloned into the parental (CMV
promoter) or a modified pIRES2-EGFP expression vector (BD
Bioscience Clonetech) containing a 554 bp PGK1 promoter. The
mouse B-Myb cDNA was mutated by PCR with primers
GGTGTGACTTAAGTAAA (fw) and TTTACTTAAGTCA-
CACC (rev).
Transfections/Nucleofections
ES cells were transfected with lipofectamine using 1.5 mgo f
shRNA plasmids in 12-well plates. Selection with 1 mg/ml of
puromycin (Sigma) was performed 24h post-transfection for a
period of three days to enrich for transfectants. Plasmid DNA was
also introduced into ES cells using the Nucleofector mouse ES Cell
Kit from Amaxa Biosystems (Cologne, Germany Cat. No VPH-
1001) according to the manufacturer’s instructions and selected
with puromycin where indicated.
Cell Cycle Analysis
DNA cell cycle analysis was measured on propidium iodide
(10 mg PI, Sigma)-stained nuclei using a FACSCalibur. Cell cycle
compartments were deconvoluted from single-parameter DNA
histograms of 10,000 cells. 5-Bromodeoxyuridine (BrdU) incorpo-
ration was measured in cells pulsed (30 min) with 10 mM BrdU
(Sigma) as described [37], using a FITC-labeled monoclonal
antibody (0.2 mg/mL) to BrdU (clone B44, Becton Dickinson).
Luciferase Reporter Constructs and Assays
A 3 kb human pou5f1 promoter and a 300 bp mouse nanog
promoter cloned upstream of the firefly luciferase gene were
employed [38]. Cells were seeded at a density of 30,000/well in
96-well plates, and reporter (75 mg), shRNA (500 ng), and pRL-
SV40 Renilla luciferase plasmid (5 ng)(Promega), as a transfection
control, were transfected into cells with Lipofectamine 2000
(Invitrogen). Firefly and Renilla luciferase activities were measured
24 or 48 h post-transfection with Dual Luciferase System
(Promega) on a Centro LB960 (Berthold Technologies) or an
Applied Byosystem TR 717 Microplate Luminometer. For over-
expression studies with PGK (or CMV)-B-Myb, data were
normalized relative to renilla luciferase (internal transfection
control) and to pGL3 luciferase to facilitate cell line comparisons.
Sister Chromatid Exchange
To estimate sister chromatid exchanges (SCE) as a parameter of
recombinatorial events, sister chromatids of the metaphase
chromosomes were differentially stained after mitotic division as
described [39]. A SCE was scored each time a color switch
between dark or light sister chromatids occurred, and chromo-
somal aberrations, including chromosomal breakage and frag-
mentation was assessed as previously described [40].
Chromatin Immunoprecipitation (ChIP)
Chromatin immunoprecipitation (ChIP) was performed as
described in the EZ-Chip Kit (Catalog #17–371, Upstate).
Briefly, mouse ES cells were cross-linked in 1% formaldehyde in
phosphate-buffered saline (PBS), and lysed in the presence of a
protease inhibitor cocktail. The chromatin was sheared to an
average of 200–800 bp, following sonication on ice using the Sonic
Dismembrator 100 (Fisher). Immunoprecipitation and DNA
recovery were performed overnight. Antibodies to rabbit IgG
(Santa Cruz, Cat No. sc-2027) were employed as a negative
Table 4. Primers used for qRT-PCR analyses
Target Primer
Nanog FW: TTTCAGAAATCCCTTCCCTCG
RV: CGTTCCCAGAATTCGATGCT
A-Myb FW: CGCGCCTATGCGGTACTT
RV: TCAGCATATTGAAGGTCATCATCCT
B-Myb FW: GTGAGGCAGTTTGGACAGCAA
RV: GGATTCAAAACCCTCAGCCA
C-Myb FW: GTGAGGCAGTTTGGACAGCAA
RV: GGATTCAAAACCCTCAGCCA
Oct4 FW: CAATGCCGTGAAGTTGGAGA
RV: GCTTCAGCAGCTTGGCAAAC
H1F0 FW: AGATCGCGAGTCAGGTTCTG
RV: GTGGAGTTCTCGGTCATGGT
Histone 1 (H1F0) was used as an internal control for PCR reactions for
normalization purposes. Pre-designed primers were also purchased from
Applied Biosystems (TaqManH Gene Expression Assays) for detection of the
following transcripts: Sox1, Utf1, CoupTf, Fgf5, Nestin, Sox17, Hdac2, Actin,
Cdx2, Hand1.
doi:10.1371/journal.pone.0002478.t004
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cipitated DNA were analyzed by PCR [GC-Rich PCR system
(Roche)] for binding of B-MYB.
EMSAs
Nucleoextracts from R1 ES cells were prepared with the
CelLytic
TM NuCLEAR
TM Extraction Kit (Sigma) or purchased
(Hela Nuclear Extract, Upstate Biotechnology, USA). EMSAs
were performed with a LightShift Chemiluminescent EMSA Kit
(Pierce, USA) according to the manufacturer’s instructions.
Oligonucleotide sequences were as follows: hOct4 Putative B-
Myb binding site - CGGGAGACACAACTGGCGCCCCTC;
Mutant binding site: CGGGAGACAATTATGGCGCC-
CCTC; and consensus B-Myb binding site - AGATGT-
CGCCCCTGGTGGACAACATCG [18]. Supershift assays
were performed by adding 1 mg of a polyclonal antibody
to B-Myb (Santa Cruz Biotechnology, Inc), and compe-
titions were performed in the presence of a 200-fold
excess of unlabeled oligonucleotide DNA cassette.
Cell Viability Assay and Apoptosis
ES cells, seeded at a density of 10,000 and 15,000/well in a 96-
well plate, were transfected with 0.5 mg of shRNA plasmid. The
WST-1 cell proliferation assay kit (Roche) was employed
according to the manufacturer’s instructions with 10 ml of WST
reagent in 100 ml of medium per well. For apoptosis, fragmented
genomic DNA was detected following size fractionation on agarose
gels, and all measurements were normalized to total cellular
protein [41]. The proportion of apoptotic cells was also
determined using Annexin V-FITC Apoptosis Kit (BD Bioscienc-
es) by fluorescence-activated cell sorting (FACS) performed on a
FACSVantage (BD Biosciences).
Statistical Analyses
Results are presented as mean6S.E.M. Non-parametric
statistical analyses, including the Mann-Whitney U test or the
Kolmogorov-Smirnov two-sample test, and analyses of variance
(ANOVA) followed by multiple comparisons of means by a
Student-Newman-Keuls’ procedure were used to evaluate differ-
ences between means of experimental groups. A Chi-square test
was used to determine differences with categorical values. P values
less than 0.05 were considered as statistically significant.
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